Abstract
Empirical antibiotic selection often fails to be optimal targeted in the era of increasingly common resistant organisms. We prospectively evaluated the usefulness or rapid AST for optimal antibiotic selection by infectious disease (ID) physicians in patients with bacteremia of Gram-positive organisms. QMAC-dRAST results led to optimal antibiotic treatment in 33 (89.2%) of the 37 cases receiving non-optimal targeted antibiotics. Optimal targeted treatments based on QMAC-dRAST results were possible in 133 (97.1%) of the 137 cases. In conclusion, the introduction of rapid phenotypic AST can help increase the selection of optimal targeted antibiotics during the early period of bacteremia.
Competing Interest Statement
S. H., D. Y. K. and S. K. are employees of QuantaMatrix Inc.,which is developing and commercializing the QMAC-dRAST technology, and have equity interest in QuantaMatrix Inc. T. S. K., P. G. C. and W. B. P. are consultants for QuantaMatrix Inc. All other authors: none to declare.
Funding Statement
This work was supported by the Korean Health Technology R&D Project, Ministry of Health&Welfare, Republic of Korea (GrantNo. HI13C-1468).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of Seoul National University Hospital (Protocol No. 1707-028-867), which waived the need forwritten informed consent from the patients.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors